
Stephen Scott Dominy MD
Associate Professor, Psychiatry, UCSF School of Medicine
Join to View Full Profile
1001 Potrero AveRm 7MSan Francisco, CA 94110
Phone+1 415-206-5612
Fax+1 415-206-8942
Are you Dr. Dominy?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Stephen Dominy, MD is a board certified psychiatrist in San Francisco, California. He is currently licensed to practice medicine in California and Ohio. He is an Associate Professor at UCSF School of Medicine.
Education & Training
- Wright State University Boonshoft School of MedicineClass of 1995
Certifications & Licensure
- CA State Medical License 1997 - 2026
- OH State Medical License 1979 - 1995
- American Board of Psychiatry and Neurology Psychiatry
Publications & Presentations
PubMed
- 4 citationsUltrastructural localization of Porphyromonas gingivalis gingipains in the substantia nigra of Parkinson's disease brains.Florian Ermini, Victoria F Low, Jennifer J Song, Adelie Y S Tan, Richard L M Faull
NPJ Parkinson's Disease. 2024-04-25 - 15 citationsTreatment of Porphyromonas gulae infection and downstream pathology in the aged dog by lysine-gingipain inhibitor COR388.Shirin Arastu-Kapur, Mai Nguyen, Debasish Raha, Florian Ermini, Ursula Haditsch
Pharmacology Research & Perspectives. 2020-02-01 - 55 citationsAlzheimer's Disease-Like Neurodegeneration in Porphyromonas gingivalis Infected Neurons with Persistent Expression of Active Gingipains.Ursula Haditsch, Theresa Roth, Leo Rodriguez, Sandy Hancock, Thomas E. Cecere
Journal of Alzheimer's Disease. 2020-01-01
Press Mentions
- Cortexyme to Present New Data at AAIC 2021July 22nd, 2021
- Cortexyme Announces Partnership with Parkinson Study Group and Upcoming Alzheimer’s Disease Data PresentationMarch 8th, 2021
- Pfizer, Verily-Backed Alzheimer's Biotech Cortexyme Hit by FDA Partial Hold over Liver ToxicityFebruary 16th, 2021
- Join now to see all